Pfizer investing $120M to boost US COVID-19 treatment production

Pfizer introduced Monday that it’s investing $120 million to boost production of its COVID-19 treatment tablets in america.  

The transfer will create greater than 250 jobs at its plant in Kalamazoo, Mich., the corporate stated, because it appears to be like to enhance production of Paxlovid. 

The Michigan plant will turn into the first international supply of energetic substances for Paxlovid, as the corporate appears to be like to make 120 million treatment programs this yr, Pfizer chief international provide officer Mike McDermott informed the Detroit Free Press.    

The funding “will enable Pfizer to enhance provide by an extra 4 million packs of Paxlovid, permitting us to meet international demand and assist enhance general entry,” stated Pfizer spokeswoman Julia Cohen.  

Growing availability and use of Paxlovid has been a major aim of the Biden administration. Well being officers have acknowledged that within the early days after it was licensed in December, provide was restricted and lots of docs have been reluctant to prescribe for all however the highest-risk sufferers.  

After efforts to get the phrase out about expanded provide and availability, White Home COVID-19 response coordinator Ashish Jha touted final week that there at the moment are 30,000 prescriptions for the treatment per day within the U.S.  

Paxlovid is seen as a key a part of making COVID-19 extra manageable, on condition that the treatment has been proven to cut back the danger of hospitalization or dying by round 90 %.  

Thus far, Pfizer has shipped 12 million programs globally to 37 nations, together with 5 million to the U.S., the corporate stated.  

“By rising production at our Michigan facility, we’re each serving to sufferers world wide and increasing essential manufacturing innovation to the U.S,” Pfizer CEO Albert Bourla stated in a press release. 

Leave a Reply

%d bloggers like this: